A5085871438- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Ocular Oncology and Treatments
- Retinal Imaging and Analysis
- Glaucoma and retinal disorders
- Retinoids in leukemia and cellular processes
- Ocular Diseases and Behçet’s Syndrome
- Drug-Induced Ocular Toxicity
- Complement system in diseases
Augenklinik Heidelberg
1997
<h3>Objective</h3> To describe fluorescein angiographic guidelines for the use of verteporfin therapy in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or other conditions based on 2-year vision outcomes from Treatment Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation and Verteporfin Therapy(VIP) Trial. <h3>Methods</h3> Three multicenter, double-masked, placebo-controlled randomized clinical trials...
<h3>Objective</h3> To compare the treatment effect and safety of photodynamic therapy with verteporfin using a standard (SF) or reduced (RF) light fluence rate that placebo in patients subfoveal minimally classic choroidal neovascularization (CNV) age-related macular degeneration. <h3>Design</h3> Phase 2, multicenter, double-masked, placebo-controlled, randomized clinical trial. <h3>Setting</h3> Nineteen ophthalmology practices North America Europe. <h3>Participants</h3> Patients initial...
Abstract Background To report visual outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy for exudative age-related macular degeneration (AMD) in a real-life setting. Patients and Methods Retrospective case series consecutive patients treated with either ranibizumab and/or aflibercept monolateral or bilateral AMD. A physician established the indication treatment administered injections. An independent confirmed primary treatment. Pro Re Nata Treat Extend regimen were used....